Medical Diagnostics Anywhere.
Medical Diagnostics Anywhere.
SAW Dx is an emerging point of care diagnostic (POC) device design and manufacturing venture focused on exploiting Acoustic-Flow technology based on the use of surface acoustic waves technology developed in the laboratory of Professor Jon Cooper, University of Glasgow.
The Acoustic-Flow technology utilises the interaction of Surface Acoustic Waves (SAW) with a patient sample to drive a diagnostic test. The interactions are controlled by microstructures patterned on the surface of disposable chips, to shape sound in particular ways in a frequency dependant manner. Functions possible include fluid movement, mixing, particle patterning, enrichment, opening cells to release DNA and temperature cycling of a sample. Acoustic-Flow technology means that samples can be processed on-chip (no preprocessing required) and complex microfluidics are avoided.
The SAW Dx business model is based on providing product and technology solutions to life sciences and diagnostics companies seeking to enhance their diagnostic product offerings through innovative point of care use.
11thAugust 2017. SAW Dx appoints two new staff
SAW Dx has appointed two senior scientists to work on its site at Biocity. They will support company’s developments of STI diagnostic tests at the point of care.
18thApril 2017. SAW Dx is recruiting
SAW Dx is looking for one assay scientist and one engineering scientist, based in Scotland, to support the development of new prototypes for the diagnosis of sexually transmitted diseases at the point of care.
Deadline 19th May 2017
1st March 2017. SAW Dx secures £1.85m funding boost to develop STI diagnostic POC prototype
Full press release.
SAW Dx, a medical technology spinout founded at the University of Glasgow , has successfully closed an investment round of £750k with IP Group, a developer of intellectual property-based businesses, and the Scottish Investment Bank, the investment arm of Scottish Enterprise.
The funding agreement comes just weeks after SAW Dx also secured £1.1m in support from the UK Government’s Biomedical Catalyst fund. This £1.85m injection of capital will help secure its route to the market for new products in infectious disease diagnostics.
SAW Dx is a technology development company providing solutions to the life sciences and diagnostics industry through the following routes:
SAW Dx provides services in the design, build and testing of products incorporating its Acoustic-Flow technology.
Make an Enquiry
Prof Jon Cooper – Director & Academic Founder;. Vice Principal for Knowledge Exchange in the University of Glasgow. Jon holds the Wolfson Chair in Biomedical Engineering; Fellow of the Royal Society of Edinburgh; Fellow of Royal Academy of Engineering; Royal Society Wolfson Research Merit Award. ERC Advanced Investigator. Spin-out companies include Clyde Biosciences.
Dr Kate Rowley, Director, IP Group plc – represents the investment company IP Group plc on the Board. She has over 20 years’ experience in the life sciences sector, working in the NHS, large pharma, public and private sectors.
Prof Steve Beaumont, OBE, Director, GU Holdings Limited – Fellow of the Royal Society of Edinburgh; Fellow of Royal Academy of Engineering; Vice Principal Emeritus; Director QUANTIC, the UK Quantum Imaging Hub; PI CENSIS, the Sensors & Imaging Systems Innovation Centre; University of Glasgow University of Glasgow
Steve Beaumont is a Chartered Engineer (CEng). He has significant experience in developing spin-out companies. Steve represents the University’s interests on the Board through its subsidiary GU Holdings Limited.
Dr. Julien Reboud – founder is a Lecturer in the division of Biomedical Engineering at the Glasgow University (UK). He is a co-inventor of the acoustic technology, for which he was awarded The Royal Academy of Engineering ERA Foundation Entrepreneurs prize (2013).
Dr. Rab Wilson – founder Is a post-doctoral research assistant in Glasgow. He studied Mathematics with Theoretical Physics at the University of Aberdeen and after an MSc. in Advanced Materials at Cranfield University, obtained an industrially-funded PhD investigating ferroelectric thin films. He is a co-inventor of the SAW Dx technology.
Make an Enquiry
The technology utilises the interaction of Surface Acoustic Waves (SAW) with a patient sample to drive a diagnostic test. The interactions are controlled by microstructures patterned on the surface of disposable chips, to shape sound in particular ways in a frequency dependant manner. Demonstrated functions include fluid movement, mixing, particle patterning, enrichment, opening cells to release DNA and temperature cycling of a sample. Acoustic-Flow technology means that samples can be processed on-chip (no pre-processing required) and complex micro-fluidics are avoided.
Make an Enquiry
A point of care ‘board and wires’ prototype for use in rapid diagnosis of Sexually Transmitted Infections (STI’s) specifically syphilis and HSV (types 1&2) from the same patient sample has been constructed and tested, with funding from an ERC advanced fellowship. The assays are proprietary to the NHS and SAW Dx is providing the technology platform. The next step is to perform a proof-of-concept study (first-in-man) to demonstrate competitive advantages.
Current lab tests require the patient to return to the clinic days later, leading just over one third of people not returning in the UK, who have to be followed up. The SAW Dx platform enables to break the cycle of infection by allowing treatment before people leave the clinic and do not return.
Development of a point of care demonstrator reader and disposable cartridge for use with existing diagnostic assays for tuberculosis (including latent TB). Latent TB (when the patient is infected but without symptoms) is particularly hard to detect and with 10% of these patients going on to develop full TB then new detection methods are required.
Infectious diseases continue to decimate human (and animal) health in many parts of the world. Malaria afflicts nearly 300 million people each year, killing over 0.6 million, mainly children. Other diseases such as the trypanosomiases (African and American) and leishmaniases affect many millions the world over and helminth infections run into the billions. In many instances methods exist to manage diseases caused by these infections. However, in order to implement suitable control strategies, it is necessary to first make accurate and sensitive diagnosis of the disease.
The SAW Dx team, in partnership with parasitologists at the University of Glasgow, has built a low power (battery-operated) plaform, to enrich parasites and perform cell lysis and molecular detection, on low-cost disposable chips.
SAW DX Ltd
11 The Square
University of Glasgow
Glasgow, G12 8QQ
Professor Jon Cooper